Personalized medicine for lung cancer: new challenges for pathology.
about
Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniquesEpigenetics advancing personalized nanomedicine in cancer therapyOptimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemEBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.Ready or not? Lung cancer diagnosis in 2015.Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsEnteric adenocarcinoma lung: a rare presentation in an Omani womanLung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersPredicting non-small cell lung cancer prognosis by fully automated microscopic pathology image featuresFolic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment.Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer.Endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer diagnosis and staging.Minimal requirements for the molecular testing of lung cancer.Novel teatment options in early-stage non-small-cell lung cancer.The impact of immunohistochemistry on the classification of lung tumors.NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma.miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.Chinese expert consensus statement on issues related to small specimen sampling of lung cancer.Morphological and genetic classification of lung cancer: variation in practice and implications for tailored treatment.Investigation of tissue cellularity at the tip of the core biopsy needle with optical coherence tomography.Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.Consistent mutation status within histologically heterogeneous lung cancer lesions.Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
P2860
Q26778702-AB6675CF-89FB-48C5-827F-106EEBCD4985Q27010637-395E1A3E-6BD4-44BB-B2A6-882FCAAE16BBQ34515855-2DBC9DDB-3DE4-46A9-B594-93A54507C3C4Q34608597-043A8E69-1241-4C34-99D7-5A6AFB8D6EBAQ35035831-0D450DBF-CA18-4213-B921-A445368A1155Q35934215-319E9024-0BE3-46FB-AC33-633F50ADEFDEQ35934241-E5D88F65-9E71-480E-8510-F0C337A701F0Q36203525-51ED80FD-AA83-4346-B418-83FC80D095DAQ36703631-967C47ED-31B7-4E0D-9843-82E3655E1580Q36962487-68CBA146-6A26-4B7A-8C9B-B6B7FDE1658FQ37188409-9081487D-4B6B-4D9E-AF0E-75FFA1D59377Q37190264-DE83D26E-D68F-48A7-8D92-406BC52E9273Q37290519-33737904-0CC0-4A3D-9EC3-F801BBB445BBQ38025627-0FEE9B68-E256-4053-851F-0620060BF870Q38097519-7F344F2D-9C79-4EEE-BE36-238508FBFF34Q38203468-C76D7889-5178-496B-9405-AF2F103A8AB1Q38258089-1AD5B671-37CA-4B55-BF6B-3C827FFC7AD7Q38286398-66D6746C-B42D-4D83-993D-7C2C7B332EE1Q38390170-C778B0DA-5E0D-4FEF-A2D3-44B57FF9D9CAQ38555895-0A364A41-9CA6-4380-BA7C-A1D4241F8E46Q38822314-77061A4F-6AF5-4527-8556-6F10A6F9F0F7Q39103568-C8A9EF2C-13C3-45D9-8BA0-0503A78094DDQ40466065-0F4C4F80-8758-482C-BFA6-5F6F46242382Q41585672-0BC222FB-FC03-4539-AA2B-AEA74586E809Q41643086-552C5682-96CE-46B8-8C58-17DD1ED5C3C7Q51733139-65513BCE-0E3C-4E4F-A9D3-B9D53C36AB05Q54340079-3BABF1CE-B81F-4B74-B0B7-5278F6D37532Q54520483-21C2037A-D3A2-41EB-822D-33E602068F36Q57213617-9A017E88-FA52-44A6-8A11-C5968FED9C39
P2860
Personalized medicine for lung cancer: new challenges for pathology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Personalized medicine for lung cancer: new challenges for pathology.
@en
Personalized medicine for lung cancer: new challenges for pathology.
@nl
type
label
Personalized medicine for lung cancer: new challenges for pathology.
@en
Personalized medicine for lung cancer: new challenges for pathology.
@nl
prefLabel
Personalized medicine for lung cancer: new challenges for pathology.
@en
Personalized medicine for lung cancer: new challenges for pathology.
@nl
P2860
P1433
P1476
Personalized medicine for lung cancer: new challenges for pathology.
@en
P2093
Keith M Kerr
P2860
P304
P356
10.1111/J.1365-2559.2011.03854.X
P577
2011-09-14T00:00:00Z